Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow GERON CORP

Get SEC filing alerts via email and in your feed for GERON CORP

GERN GERNW

GERON CORP

About GERON CORP

Geron Corporation is a biopharmaceutical company focused on developing telomerase inhibitors for hematologic malignancies. Its flagship product, RYTELO (imetelstat), targets blood cancers like myelodysplastic syndromes and myelofibrosis, aiming to modify disease progression. The company leverages Nobel-winning science, holds key patents, and operates in the U.S. and Europe, emphasizing innovative therapies with potential for significant market impact and regulatory exclusivity.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from GERON CORP

1
1
GERON CORP Geron Corporation Reports 31% Revenue Increase to $51.8 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
GERON CORP Geron Corporation Reports $183.6 Million Revenue and $83.5 Million Net Loss for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
GERON CORP Geron Corporation Reports 67% Revenue Growth to $47.2 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
GERON CORP Geron Corporation Reports $49M Revenue in Q2 2025, Significant Growth from Previous Year

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
GERON CORP Geron Corporation Reports $39.6 Million Revenue in Q1 2025, Driven by RYTELO Launch

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
GERON CORP Geron Corporation Reports Significant Revenue Growth, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments